Delisting risk
Silo Pharma (SILO)
Licenses preclinical CNS therapies while building QwikAgents and a cryptocurrency treasury.
$2.49
Pre-market−0.07 (−2.92%)
At close$2.57(+5.12%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Research & development | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| Operating income | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −2 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −2 | −1 |
| Net income from continuing operations | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −2 | −1 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −2 | −1 |
| EPS, basic | −$0.21 | −$5.85 | −$4.20 | −$4.65 | −$3.30 | −$5.85 | −$3.45 | −$2.85 | −$1.80 | −$0.99 | −$1.80 | −$0.76 |
| EPS, diluted | −$0.21 | −$5.85 | −$4.20 | −$4.65 | −$3.30 | −$5.85 | −$3.45 | −$2.85 | −$1.80 | −$0.99 | −$1.80 | −$0.76 |
| Weighted average shares, basic | 3 | — | — | — | — | — | — | — | — | — | 1 | 1 |
| Weighted average shares, diluted | 3 | — | — | — | — | — | — | — | — | — | 1 | 1 |
| EBITDA | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −2 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −2 | −1 |